Pressmeddelande

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2023

Stockholm, Sweden–April 11th 2024: Modus Therapeutics Holding AB (publ) (”Modus Therapeutics”) announces today that the company is publishing the annual report for 2023.

The annual report is now available to download at the company’s website: https://www.modustx.com/investors/financial-reports.html

About Modus Therapeutics and sevuparin
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Source:MFN

Tillbaka

Det verkar som att du använder en annonsblockerare

Logga in på di.se

Inte prenumerant än?

Tillgång till alla nyhetsbrev med en prenumeration